Propionate is the most plausible exploratory monotherapy candidate only because it may have somewhat more realistic systemic signaling potential than butyrate, but the evidence base is thin and not specific to aggregate clearance. It should remain a comparator arm in PK/PD studies, not a primary translational program.
At realistic exposure levels, SCFAs are more likely to act as receptor-mediated endocrine signals than as direct neuronal epigenetic modulators. Activation of intestinal FFAR2/FFAR3 on L cells could raise GLP-1 signaling and secondarily improve neuronal stress resistance or proteostasis, but the current evidence supports mediation plausibility more than proven alpha-synuclein clearance.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
FFAR3 recurs across 2 selected hypotheses with aligned directionality in protein aggregation, proteostasis stress response.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
1/11
dimensions won
Propionate may outperform acetate or but
11/11
dimensions won
Physiological SCFAs may confer indirect
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.49
0.79
Evidence
0.32
0.60
Novelty
0.58
0.62
Feasibility
0.55
0.72
Impact
0.34
0.69
Druggability
0.46
0.80
Safety
0.57
0.71
Competition
0.51
0.56
Data
0.29
0.61
Reproducible
0.30
0.55
KG Connect
0.50
0.50
Score Breakdown
Dimension
Propionate may outperform acet
Physiological SCFAs may confer
Mechanistic
0.490
0.790
Evidence
0.320
0.600
Novelty
0.580
0.620
Feasibility
0.550
0.720
Impact
0.340
0.690
Druggability
0.460
0.800
Safety
0.570
0.710
Competition
0.510
0.560
Data
0.290
0.610
Reproducible
0.300
0.550
KG Connect
0.500
0.500
Evidence
Propionate may outperform acetate or butyrate at physiologic
No evidence citations yet
Physiological SCFAs may confer indirect anti-synuclein benef
No evidence citations yet
Debate Excerpts
Propionate may outperform acetate or butyrate at p
4 rounds · quality: 0.63
Persona-Theorist
Below, I assume the key translational question is whether **physiologically achievable circulating SCFAs (roughly low-μM, especially for butyrate/propionate outside the colon)** can alter **α-synuclei...
Persona-Skeptic
**Overall**
The main weakness across all six hypotheses is the same: the cited literature mostly shows that SCFAs can change PD-like phenotypes under model-specific, often pharmacologic conditions, bu...
Persona-Domain Expert
Physiologic low-μM systemic SCFAs do not look like a standalone drug-ready route for driving meaningful brain α-syn clearance. The surviving ideas are narrower: a gut-first signaling effect, a GLP-1-l...
Persona-Synthesizer
{
"ranked_hypotheses": [
{
"title": "Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-first or ENS-first mechanism rather than direct brain exposure",
"d...
Physiological SCFAs may confer indirect anti-synuc
4 rounds · quality: 0.63
Persona-Theorist
Below, I assume the key translational question is whether **physiologically achievable circulating SCFAs (roughly low-μM, especially for butyrate/propionate outside the colon)** can alter **α-synuclei...
Persona-Skeptic
**Overall**
The main weakness across all six hypotheses is the same: the cited literature mostly shows that SCFAs can change PD-like phenotypes under model-specific, often pharmacologic conditions, bu...
Persona-Domain Expert
Physiologic low-μM systemic SCFAs do not look like a standalone drug-ready route for driving meaningful brain α-syn clearance. The surviving ideas are narrower: a gut-first signaling effect, a GLP-1-l...
Persona-Synthesizer
{
"ranked_hypotheses": [
{
"title": "Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-first or ENS-first mechanism rather than direct brain exposure",
"d...